News

Revised Phase 2 Strategy Targets Event-Free Survival in Primary Head and Neck Cancer through Checkpoint Inhibitor Combination ...
A new study has found that patients with metastatic non–small cell lung cancer and pre-existing rheumatoid arthritis have similar overall survival to those without RA when treated with immune ...
During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.
Botensilimab/balstilimab (BOT/BAL) synergistically activate and sustain immune attack, offering a promising new strategy for ...
Adding SCIB1 or iSCIB1+ to standard treatments helped more patients with advanced melanoma respond and live longer without ...
RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
Gilead Sciences and Arcus Biosciences are conducting a Phase 3 clinical study titled A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combinati ...
Colorectal cancer is one of the most frequently diagnosed cancers worldwide and a leading cause of cancer-related deaths.
The trial will include patients with non-small cell lung, colorectal, head and neck, and cutaneous cancers with EGFR amplification.
Some lung cancers do not respond well to immunotherapy, a treatment that helps the body’s immune system attack cancer. But a new study shows that radiation therapy might help solve this problem. The ...